On the mechanisms underlying 3,4-methylenedioxymethamphetamine toxicity: The dilemma of the chicken and the egg

Neuropsychobiology

Volumn 60, Issue 3-4, 2009, Pages 119-129

  Puerta, E ^a   Hervias, I ^a   Aguirre, Norberto ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

3,4 Methylenedioxymethamphetamine; 5 Hydroxytryptamine; Dopamine; Hyperthermia; Metabolism; Neurotoxicity; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 AMINOBUTYRIC ACID RECEPTOR; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ANTISENSE OLIGONUCLEOTIDE; CLOMETHIAZOLE; CYTOCHROME P450 2D6; DEOXYGLUCOSE; DIZOCILPINE; DOPAMINE; DRONABINOL; KETANSERIN; MALEIC ACID DIETHYL ESTER; MAZINDOL; METIROSINE; MOFEGILINE; MONOAMINE OXIDASE B INHIBITOR; N TERT BUTYL ALPHA PHENYLNITRONE; N(G) NITROARGININE METHYL ESTER; PENTOBARBITAL; REACTIVE OXYGEN METABOLITE; SELEGILINE; SEROTONIN;

DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DRUG ABUSE; DRUG MECHANISM; HUMAN; HYPERTHERMIA; NERVE FIBER; NERVE FIBER DEGENERATION; NEUROTOXICITY; NONHUMAN; OXIDATION; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM;

ANIMALS; BRAIN; DOPAMINE; HALLUCINOGENS; HUMANS; MODELS, NEUROLOGICAL; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE;

EID: 70449485053     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000253548     Document Type: Review

References (130)

1. Liechti ME, Vollenweider FX: Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol 2001; 16: 589-598.
2. Vollenweider FX, Gamma A, Liechti M, Huber T: Psychological and cardiovascular effects and short-term sequelae of MDMA ('ecstasy') in MDMA-naive healthy volunteers. Neuropsychopharmacology 1998; 19: 241-251.
3. Baumann MH, Wang X, Rothman RB: 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 2007; 189: 407-424.
4. Schifano F: A bitter pill: overview of ecstasy (MDMA, MDA)-related fatalities. Psychopharmacology (Berl) 2004; 173: 242-248.
5. Morgan MJ: Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berl) 2000; 152: 230-248.
6. Parrott AC: Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 2002; 71: 837-844.
7. Parrott AC: MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. J Psychopharmacol 2006; 20: 147-163.
8. Schmidt CJ, Wu L, Lovenberg W: Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. Eur J Pharmacol 1986; 124: 175-178.
9. Schmidt CJ: Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 1987; 240: 1-7.
10. Aguirre N, Ballaz S, Lasheras B, Del Río J: MDMA ('Ecstasy') enhances 5-HT1A receptor density and 8-OH-DPAT-induced hypothermia: blockade by drugs preventing 5-hydroxytryptamine depletion. Eur J Pharmacol 1998; 346: 181-188.
11. Barrionuevo M, Aguirre N, Del Río J, Lasheras B: Serotonergic deficits and impaired passive-avoidance learning in rats by MDEA: a comparison with MDMA. Pharmacol Biochem Behav 2000; 65: 233-240.
12. Hatzidimitriou G, McCann UD, Ricaurte G.A: Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4- methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 1999; 19: 5096-5107.
13. Hatzidimitriou G, Tsai EH, McCann UD, Ricaurte GA: Altered prolactin response to M-chlorophenylpiperazine in monkeys previously treated with 3,4-methylenedioxymethamphetamine (MDMA) or fenfluramine. Synapse 2002; 44: 51-57.
14. McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA: Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C] DASB. Neuropsychopharmacology 2005; 30: 1741-1750.
15. Stone DM, Johnson M, Hanson GR, Gibb JW: Acute inactivation of tryptophan hydroxylase by amphetamine analogs involves the oxidation of sulfhydryl sites. Eur J Pharmacol 1989; 172: 93-97.
16. Aguirre N, Galbete JL, Lasheras B, Del Río J: Methylenedioxymethamphetamine induces opposite changes in central pre- and postsynaptic 5-HT1A receptors in rats. Eur J Pharmacol 1995; 281: 101-105.
17. Battaglia G, Yeh SY, O'Hearn E, Molliver ME, Kuhar MJ, De Souza EB: 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 1987; 242: 911-916.
18. Hervias I, Lasheras B, Aguirre N: 2-Deoxy- D -glucose prevents and nicotinamide potentiates 3,4-methylenedioxymethamphetamine- induced serotonin neurotoxicity. J Neurochem 2000; 75: 982-990.
19. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS: Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 1987; 241: 338-345.
20. Schmued LC: Demonstration and localization of neuronal degeneration in the rat forebrain following a single exposure to MDMA. Brain Res 2003; 974: 127-133.
21. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME: Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 1988; 8: 2788-2803.
22. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI: The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 2003; 55: 463-508.
23. Ricaurte GA, DeLanney LE, Wiener SG, Irwin I, Langston JW: 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Res 1988; 474: 359-363.
24. Ricaurte GA, Finnegan KT, Irwin I, Langston JW: Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations. Ann NY Acad Sci 1990; 600: 699-710.
25. Price LH, Ricaurte GA, Krystal JH, Heninger GR: Neuroendocrine and mood responses to intravenous L -tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users: preliminary observations. Arch Gen Psychiatry 1989; 46: 20-22.
26. McCann UD, Ridenour A, Shaham Y, Ricaurte GA: Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy'): a controlled study in humans. Neuropsychopharmacology 1994; 10: 129-138.
27. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA: Positron emission tomographic evidence of toxic effect of MDMA ('ecstasy') on brain serotonin neurons in human beings. Lancet 1998; 352: 1433-1437.
28. McCann UD, Mertl M, Eligulashvili V, Ricaurte GA: Cognitive performance in (+/-) 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') users: a controlled study. Psychopharmacology (Berl) 1999; 143: 417-425.
29. Bolla KI, McCann UD, Ricaurte GA: Memory impairment in abstinent MDMA ('Ecstasy') users. Neurology 1998; 51: 1532-1537.
30. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC: Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br J Psychiatry 1999; 175: 63-69.
31. Gerra G, Zaimovic A, Ferri M, Zambelli U, Timpano M, Neri E, Marzocchi GF, Delsignore R, Brambilla F: Long-lasting effects of (+/-)3,4- methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. Biol Psychiatry 2000; 47: 127-136.
32. Kish SJ, Furukawa Y, Ang L, Vorce SP, Kalasinsky KS: Striatal serotonin is depleted in brain of a human MDMA (ecstasy) user. Neurology 2000; 55: 294-296.
33. Buchert R, Obrocki J, Thomasius R, Vaterlein O, Petersen K, Jenicke L, Bohuslavizki KH, Clausen M: Long-term effects of 'ecstasy' abuse on the human brain studied by FDG PET. Nucl Med Commun 2001; 22: 889-897.
34. Ricaurte GA, McCann UD, Szabo Z, Scheffel U: Toxicodynamics and long-term toxicity of the recreational drug, 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Toxicol Lett 2000; 112-113: 143-146.
35. Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, Wilke F, Wartberg L, Zapletalova P, Clausen M: Long-term effects of 'ecstasy' use on serotonin transporters of the brain investigated by PET. J Nucl Med 2003; 44: 375-384.
36. Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, Schulze O, Schmidt U, Clausen M: A voxel-based PET investigation of the long-term effects of 'Ecstasy' consumption on brain serotonin transporters. Am J Psychiatry 2004; 161: 1181-1189.
37. Broening HW, Bowyer JF, Slikker W Jr: Agedependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)3,4- methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. J Pharmacol Exp Ther 1995; 275: 325-333.
38. Yuan J, Cord BJ, McCann UD, Callahan BT, Ricaurte GA: Effect of depleting vesicular and cytoplasmic dopamine on methylenedioxymethamphetamine Neurotoxicity. J Neurochem 2002; 80: 960-969.
39. Goñi-Allo B, O Mathúna B, Segura M, Puerta E, Lasheras B, De La Torre R, Aguirre N: The relationship between core body temperature and 3,4- methylenedioxymethamphetamine metabolism in rats: implications for neurotoxicity. Psychopharmacology (Berl) 2008; 197: 263-278.
40. Goñi-Allo B, Puerta E, Hervias I, Di Palma R, Ramos M, Lasheras B, Aguirre N: Studies on the mechanisms underlying amiloride enhancement of 3,4-methylenedioxymethamphetamine- induced serotonin depletion in rats. Eur J Pharmacol 2007; 562: 198-207.
41. Malberg JE, Seiden LS: Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 1998; 18: 5086-5094.
42. Sprague JE, Banks ML, Cook VJ, Mills EM: Hypothalamic-pituitary-thyroid axis and sympathetic nervous system involvement in hyperthermia induced by 3,4-methylenedioxymethamphetamine (Ecstasy). J Pharmacol Exp Ther 2003; 305: 159-166.
43. Sanchez V, O'Shea E, Saadat KS, Elliott JM, Colado MI, Green AR: Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones. J Psychopharmacol 2004; 18: 412-416.
44. Zheng Y, Laverty R: Role of brain nitric oxide in (+/-)3,4- methylenedioxymethamphetamine (MDMA)-induced neurotoxicity in rats. Brain Res 1998; 795: 257-263.
45. Yeh SY: N-tert-butyl- - -phenylnitrone protects against 3,4-methylenedioxymethamphetamine- induced depletion of serotonin in rats. Synapse 1999; 31: 169-177.
46. Darvesh AS, Gudelsky GA: The relationship between hyperthermia and glycogenolysis in 3,4-methylenedioxymethamphetamine-induced serotonin depletion in rats. Neurotoxicol Teratol 2004; 26: 571-577.
47. Green AR, O'Shea E, Colado MI: A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol 2004; 500: 3-13.
48. Colado MI, Green AR: The spin trap reagent - -phenyl-N-tert-butyl nitrone prevents 'ecstasy'- induced neurodegeneration of 5-hydroxytryptamine neurones. Eur J Pharmacol 1995; 280: 343-346.
49. Gudelsky GA: Effect of ascorbate and cysteine on the 3,4- methylenedioxymethamphetamine- induced depletion of brain serotonin. J Neural Transm 1996; 103: 1397-1404.
50. Aguirre N, Barrionuevo M, Ramírez MJ, Del Río J, Lasheras B: - -Lipoic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity. Neuroreport 1999; 10: 3675-3680.
51. Sprague J, Nichols DE: The monoamine oxidase- B inhibitor l-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J Pharmacol Exp Ther 1995; 273: 667-673.
52. Colado MI, O'Shea E, Granados R, Murray TK, Green AR: In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA (ecstasy) and p-chloroamphetamine but not the degeneration following fenfluramine. Br J Pharmacol 1997; 121: 889-900.
53. Darvesh AS, Yamamoto BK, Gudelsky GA: Evidence for the involvement of nitric oxide in 3,4-methylenedioxymethamphetamineinduced serotonin depletion in the rat brain. J Pharmacol Exp Ther 2005; 312: 694-701.
54. Colado MI, O'Shea E, Esteban B, Granados R, Green AR: In vivo evidence against clomethiazole being neuroprotective against MDMA ('ecstasy')-induced degeneration of rat brain 5-HT nerve terminals by a free radical scavenging mechanism. Neuropharmacology 1999; 38: 307-314.
55. Colado MI, O'Shea E, Granados R, Esteban B, Martin AB, Green AR: Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of dark agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration. Br J Pharmacol 1999; 126: 911-924.
56. Shankaran M, Yamamoto BK, Gudelsky GA: Mazindol attenuates the 3,4-methylenedioxymethamphetamine- induced formation of hydroxyl radicals and long-term depletion of serotonin in the striatum. J Neurochem 1999; 72: 2516-2522.
57. Shankaran M, Yamamoto BK, Gudelsky GA: Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 1999; 385: 103-110.
58. Shankaran M, Yamamoto BK, Gudelsky GA: Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT. Synapse 2001; 40: 55-64.
59. Breier JM, Bankson MG, Yamamoto BK: L - tyrosine contributes to (+/-)-3,4-methylenedioxymethamphetamine- induced serotonin depletions. J Neurosci 2006; 26: 290-299.
60. Goñi-Allo B, Ramos M, Hervias I, Lasheras B, Aguirre N: Studies on striatal neurotoxicity caused by the 3,4-methylenedioxymethamphetamine/ malonate combination: implications for serotonin/dopamine interactions. J Psychopharmacol 2006; 20: 245-256.
61. Sprague JE, Everman SL, Nichols DE: An integrated hypothesis for the axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology 1998; 19: 427-442.
62. Miller RT, Lau SS, Monks TJ: 2,5-Bis-(glutathion- S-yl)- - -methyldopamine, a putative metabolite of (+/- )-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations. Eur J Pharmacol 1997; 323: 173-180.
63. Bai F, Lau SS, Monks TJ: Glutathion and Nacetylcysteine conjugates of - -methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine- mediated neurotoxicity. Chem Res Toxicol 1999; 20: 1150-1157.
64. Bai F, Jones DC, Lau SS, Monks TJ: Serotonergic neurotoxicity of 3,4-(+/-)-methylenedioxyamphetamine and 3,4-(+/- )-methylenedioxymethamphetamine (ecstasy) is potentiated by inhibition of - -glutamyl transpeptidase. Chem Res Toxicol 2001; 14: 863-870.
65. Esteban E, O'Shea E, Camarero J, Sanchez V, Green RA, Colado MI: 3,4-methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology 2001; 154: 251-260.
66. Goñi-Allo B, Puerta E, O Mathúna B, Hervias I, Lasheras B, Le La Torre R, Aguirre N: On the role of tyrosine and peripheral metabolism in 3,4-methylenedioxymethamphetamine- induced serotonin neurotoxicity in rats. Neuropharmacology 2008; 54: 885-900.
67. Schmidt CJ, Wu L, Lovenberg W: Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. Eur J Pharmacol 1986; 124: 175-178.
68. Stone DM, Hanson GR, Gibb JW: Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats. Neuropharmacology 1987; 26: 1657-1661.
69. Logan BJ, Laverty R, Sanderson WD, Yee YB: Differences between rats and mice in MDMA (methylenedioxymethamphetamine) neurotoxicity. Eur J Pharmacol 1988; 152: 227-234.
70. McKenna DJ, Peroutka SJ: Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). J Neurochem 1990; 54: 14-22.
71. Gough B, Ali SF, Slikker W Jr, Holson RR: Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol Biochem Behav 1991; 39: 619-623.
72. Colado MI, Green AR: A study of the mechanism of MDMA ('ecstasy')-induced neurotoxicity of 5-HT neurones using chlormethiazole, dizocilpine and other protective compounds. Br J Pharmacol 1994; 111: 131-136.
73. Nash JF, Brodkin J: Microdialysis studies on 3,4- methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. J Pharmacol Exp Ther 1991; 259: 820-825.
74. Koch S, Galloway MP: MDMA-induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm 1997; 104: 135-146.
75. Gudelsky GA, Nash JF: Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin- dopamine interactions. J Neurochem 1996; 66: 243-249.
76. Schmidt CJ, Sullivan CK, Fadayel GM: Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J Neurochem 1994; 62: 1382-1389.
77. Yamamoto BK, Nash JF, Gudelsky GA: Modulation of methylenedioxymethamphetamine- induced striatal dopamine release by the interaction between serotonin and - - aminobutyric acid in the substantia nigra. J Pharmacol Exp Ther 1995; 273: 1063-1070.
78. Nash JF: Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci 1990; 47: 2401-2408.
79. Schmidt CJ, Black CK, Taylor VL, Fadayel GM, Humphreys TM, Nieduzak TR, Sorensen SM: The 5-HT2 receptor antagonist, MDL 28,133A, disrupts the serotonergic-dopaminergic interaction mediating the neurochemical effects of 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 1992; 220: 151-159.
80. Schmidt CJ, Fadayel GM, Sullivan CK, Taylor VL: 5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 1992; 223: 65-74.
81. Huang X, Nichols DE: 5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. Eur J Pharmacol 1993; 238: 291-296.
82. Gudelsky GA, Yamamoto BK, Nash JF: Potentiation of 3,4- methylenedioxymethamphetamine- induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists. Eur J Pharmacol 1994; 264: 325-330.
83. Kanthasamy A, Sprague JE, Shotwell JR, Nichols DE: Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum. Neuroscience 2002; 114: 917-924.
84. Schmidt CJ, Abbate GM, Black CK, Taylor VL: Selective 5-hydroxytryptamine2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 1990; 255: 478-483.
85. Nash JF, Nichols DE: Microdialysis studies on 3,4- methylenedioxyamphetamine and structurally related analogues. Eur J Pharmacol 1991; 200: 53-58.
86. Sprague JE, Huang X, Kanthasamy A, Nichols DE: Attenuation of 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity with the serotonin precursors tryptophan and 5-hydroxytryptophan. Life Sci 1994; 55: 1193-1198.
87. Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM: Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc Natl Acad Sci USA 1999; 96: 12079-12084.
88. Colado MI, Murray TK, Green AR: 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br J Pharmacol 1993; 108: 583-589.
89. Bankson MG, Yamamoto BK: Serotonin- GABA interactions modulate MDMA-induced mesolimbic dopamine release. J Neurochem 2004; 91: 852-859.
90. Nash JF, Meltzer HY, Gudelsky GA: Effect of 3,4- methylenedioxymethamphetamine on 3,4-dihydroxyphenylalanine accumulation in the striatum and nucleus accumbens. J Neurochem 1990; 54: 1062-1067.
91. Faraj BA, Olkowski ZL, Jackson RT: Active [3H]-dopamine uptake by human lymphocytes: correlates with serotonin transporter activity. Pharmacology 1994; 48: 320-327.
92. Hrometz SL, Brown AW, Nichols DE, Sprague JE: 3,4- methylenedioxymethamphetamine (MDMA, ecstasy)-mediated production of hydrogen peroxide in an in vitro model: the role of dopamine, the serotoninreuptake transporter, and monoamine oxidase- B. Neurosci Lett 2004; 367: 56-59.
93. Jones DC, Lau SS, Monks TJ: Thioether metabolites of 3,4- methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells. J Pharmacol Exp Ther 2004; 311: 298-306.
94. Saldana SN, Barker EL: Temperature and 3,4-methylenedioxymethamphetamine alter human serotonin transporter-mediated dopamine uptake. Neurosci Lett 2004; 354: 209-212.
95. Sanchez V, Camarero J, Esteban B, Peter MJ, Green AR, Colado MI: The mechanisms involved in the long-lasting neu - r oprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain. Br J Pharmacol 2001; 134: 46-57.
96. Schmidt CJ: Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 1987; 240: 1-7.
97. Falk EM, Cook VJ, Nichols DE, Sprague JE: An antisense oligonucleotide targeted at MAO-B attenuates rat striatal serotonergic neurotoxicity induced by MDMA. Pharmacol Biochem Behav 2002; 72: 617-622.
98. Stone DM, Johnson M, Hanson GR, Gibb JW: Role of endogenous dopamine in the central serotonergic deficits induced by methylenedioxymethamphetamine. J Pharmacol Exp Ther 1988; 247: 79-87.
99. Schmidt CJ, Black CK, Taylor VL: Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine. Eur J Pharmacol 1990; 181: 59-70.
100. Schmidt CJ, Black CK, Taylor VL: L -DOPA potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats. Eur J Pharmacol 1991; 203: 41-49.
101. Simantov R, Tauber M: The abused drug MDMA (ecstasy) induces programmed death of human serotonergic cells. FASEB J 1997; 11: 141-146.
102. Nixdorf WL, Burrows KB, Gudelsky GA, Yamamoto BK: Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate. J Neurochem 2001; 77: 647-654.
103. O'Shea E, Orio L, Escobedo I, Sanchez V, Camarero J, Green AR, Colado MI: MDMAinduced neurotoxicity: long-term effects on 5-HT biosynthesis and the influence of ambient temperature. Br J Pharmacol 2006; 148: 778-785.
104. Puerta E, Hervias I, Goñi-Allo B, Lasheras B, Jordan J, Aguirre N: Phosphodiesterase
105. inhibitors prevent 3,4-methylenedioxymethamphetamine- induced 5-HT deficits in the rat. J Neurochem 2009; 108: 755-766.
106. De La Torre R, Farre M: Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 2004; 25: 505-508.
107. De La Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Cami J: Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 2004; 26: 137-144.
108. Monks TJ, Jones DC, Bai F, Lau SS: The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity. Ther Drug Monit 2004; 26: 132-136.
109. Hiramatsu M, Kumagai Y, Unger SE, Cho AK: Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and quinone identified as its glutathione adduct. J Pharmacol Exp Ther 1990; 254: 521-528.
110. Miller RT, Lau SS, Monks TJ: Metabolism of 5-(glutathion-Syl)- - -methyldopamine following intracerebroventricular administration to male Sprague-Dawley rats. Chem Res Toxicol 1995; 8: 634-641.
111. Miller RT, Lau SS, Monks TJ: Effects of intracerebroventricular administration of 5-(glutathion-S-yl)- - -methyldopamine on brain dopamine, serotonin, and norepinephrine concentrations in male Sprague- Dawley rats. Chem Res Toxicol 1996; 9: 457-465.
112. Easton N, Fry J, O'Shea E, Watkins A, Kingston S, Marsden CA: Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of - -methyldopamine with relevance to MDA and MDMA (ecstasy). Brain Res 2003; 987: 144-154.
113. Jones DC, Duvauchelle C, Olsen CM, Lau SS, De La Torre R, Monks TJ: Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J Pharmacol Exp Ther 2005; 313: 422-431.
114. Capela JP, Macedo C, Branco PS, Ferreira LM, Lobo AM, Fernandes E, Remião F, Bastos ML, Dirnagl U, Meisel A, Carvalho F: Neurotoxicity mechanisms of thioether ecstasy metabolites. Neuroscience 2007; 146: 1743-1757.
115. Carvalho M, Remião F, Milhazes N, Borges F, Fernandes E, Monteiro Mdo C, Gonçalves MJ, Seabra V, Amado F, Carvalho F, Bastos ML: Metabolism is required for the expression of ecstasy-induced cardiotoxicity in vitro. Chem Res Toxicol 2004; 17: 623-632.
116. Carvalho M, Milhazes N, Remiao F, Borges F, Fernandes E, Amado F, Monks TJ, Carvalho F, Bastos ML: Hepatotoxicity of 3,4- methylenedioxyamphetamine and - -methyldopamine in isolated rat hepatocytes: formation of glutathione conjugates. Arch Toxicol 2004; 78: 16-24.
117. Carvalho M, Remião F, Milhazes N, Borges F, Fernandes E, Carvalho F, Bastos ML: The toxicity of N-methyl- - -methyldopamine to freshly isolated rat hepatocytes is prevented by ascorbic acid and N-acetylcysteine. Toxicology 2004; 200: 193-203.
118. Carvalho M, Hawksworth G, Milhazes N, Borges F, Monks TJ, Fernandes E, Carvalho F, Bastos ML: Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renal proximal tubular cells. Arch Toxicol 2002; 76: 581-588.
119. Capela JP, Meisel A, Abreu AR, Branco PS, Ferreira LM, Lobo AM, Remião F, Bastos ML, Carvalho F: Neurotoxicity of Ecstasy metabolites in rat cortical neurons, and influence of hyperthermia. J Pharmacol Exp Ther 2006; 316: 53-61.
120. Capela JP, Ruscher K, Lautenschlager M, Freyer D, Dirnagl U, Gaio AR, Bastos ML, Meisel A, Carvalho F: Ecstasy-induced cell death in cortical neuronal cultures is serotonin- 2A-receptor-dependent and potentiated under hyperthermia. Neuroscience 2006; 139: 1069-1081.
121. Carmo H, Brulport M, Hermes M, Oesch F, Silva R, Ferreira LM, Branco PS, Boer D, Remião F, Carvalho F, Schön MR, Krebsfänger N, Doehmer J, Bastos Mde L, Hengstler JG: Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine ('Ecstasy') cytotoxicity. Pharmacogenet Genomics 2006; 16: 789-799.
122. Easton N, Marsden CA: Ecstasy: are animal data consistent between species and can they translate to humans? J Psychopharmacol 2006; 20: 194-210.
123. Farfel GM, Seiden LS: Role of hypothermia in the mechanism of protection against serotonergic toxicity. I. Experiments using 3,4- methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX. J Pharmacol Exp Ther 1995; 272: 860-867.
124. Che S, Johnson M, Hanson GR, Gibb JW: Body temperature effect on methylenedioxymethamphetamine- induced acute decrease in tryptophan hydroxylase activity. Eur J Pharmacol 1995; 293: 447-453.
125. Malberg JE, Sabol KE, Seiden LS: Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J Pharmacol Exp Ther 1996; 278: 258-267.
126. Taraska T, Finnegan KT: Nitric oxide and the neurotoxic effects of methamphetamine and 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 1997; 280: 941-947.
127. Colado MI, Granados R, O'Shea E, Esteban B, Green AR: Role of hyperthermia in the protective action of clomethiazole against MDMA ('ecstasy')-induced neurodegeneration, comparison with the novel NMDA channel blocker AR-R15896AR. Br J Pharmacol 1998; 124: 479-484.
128. Colado MI, Esteban B, O'Shea E, Granados R, Green AR: Studies on the neuroprotective effect of pentobarbitone on MDMA-induced neurodegeneration. Psychopharmacology 1999; 142: 421-425.
129. O'Shea E, Easton N, Fry JR, Green AR, Marsden CA: Protection against 3,4-methylenedioxymethamphetamine- induced neurodegeneration produced by glutathione depletion in rats is mediated by attenuation of hyperthermia. J Neurochem 2002; 81: 686-695.
130. Morley KC, Li KM, Hunt GE, Mallet PE, McGregor IS: Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA ('Ecstasy') in rats. Neuropharmacology 2004; 46: 954-965.